News
UTHR
364.70
+0.50%
1.82
United Therapeutics: Strong Market Position and Growth Prospects with Strategic Pipeline and Capital Management
TipRanks · 4h ago
United Therapeutics to Present at J.P. Morgan Conference
TipRanks · 1d ago
Weekly Report: what happened at UTHR last week (0106-0110)?
Weekly Report · 2d ago
United Therapeutics Is Maintained at Buy by UBS
Dow Jones · 6d ago
UBS Maintains Buy on United Therapeutics, Raises Price Target to $475
Benzinga · 6d ago
Trump Trade: New administration to invest $20B to build data centers
TipRanks · 6d ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NASDAQ · 6d ago
UNITED THERAPEUTICS CORP <UTHR.O>: UBS RAISES TARGET PRICE TO $475 FROM $415
Reuters · 6d ago
United Therapeutics price target raised to $475 from $415 at UBS
TipRanks · 6d ago
Weekly Report: what happened at UTHR last week (1230-0103)?
Weekly Report · 01/06 09:15
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 01/06 06:00
How The Parts Add Up: FPX Targets $131
NASDAQ · 01/02 13:07
How Is The Market Feeling About United Therapeutics?
Benzinga · 01/01 20:00
Notable ETF Inflow Detected - XBI, NBIX, BMRN, UTHR
NASDAQ · 12/30/2024 15:49
Investing in United Therapeutics (NASDAQ:UTHR) five years ago would have delivered you a 316% gain
Simply Wall St · 12/30/2024 10:08
Weekly Report: what happened at UTHR last week (1223-1227)?
Weekly Report · 12/30/2024 09:14
The Zen Ten - My Top Picks For 2025
Seeking Alpha · 12/29/2024 21:25
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
NASDAQ · 12/25/2024 14:45
Weekly Report: what happened at UTHR last week (1216-1220)?
Weekly Report · 12/23/2024 09:14
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/20/2024 15:50
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.